MR-guided percutaneous ethanol ablation of hepatocellular carcinomas before liver transplantation.

It was the objective of this study to evaluate MR-guided, percutaneous ethanol injection of hepatocellular carcinoma in ten patients scheduled for liver transplantation. Using a 0.2 T open MR scanner (Magnetom Open, Siemens Medical Systems, Erlangen, Germany) and percutaneous instillation of ethanol, 12 liver tumors (median tumor volume, 6.3; range, 0.6-43.2 ccm) were treated. Coagulation necrosis, morbidity, and post-transplant histology were assessed. No major complications were observed. A mean of 16.4+/-11.4 ml ethanol was injected for each tumor. The median volume of the ablation necrosis was 12.3 (range, 0.3-48.3) ccm. Three tumors were retreated and complete radiological necrosis before liver transplantation was found in eight of 12 tumors (67%). One patient developed multifocal disease and was excluded from transplantation; thus nine of ten patients underwent liver transplantation within 3.9+/-3.1 months. In the explants, satellite nodules (n = 2), new liver tumors (n = 2) and a complete necrosis were found in five of 12 treated tumors (42%). During follow-up (median 41.3; range, 0.4-86.1 months), three patients died, but no tumor-seeding or post-transplantation recurrence occurred. MR-guided ethanol injection is feasible, and may delay tumor progression. However, the local recurrence rate is high, and the spatial resolution of a low-field MR scanner limits the detection of small tumors.